Acceleron reports 3Q loss

CAMBRIDGE, Mass. (AP) _ Acceleron Pharma Inc. (XLRN) on Tuesday reported a loss of $25.5 million in its third quarter.

On a per-share basis, the Cambridge, Massachusetts-based company said it had a loss of 65 cents.

The results exceeded Wall Street expectations. The average estimate of six analysts surveyed by Zacks Investment Research was for a loss of 67 cents per share.

The clinical stage biotech developing protein therapeutics for cancer and rare diseases posted revenue of $3 million in the period, falling short of Street forecasts. Four analysts surveyed by Zacks expected $3.1 million.

Acceleron shares have climbed 46 percent since the beginning of the year. The stock has risen 36 percent in the last 12 months.

This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on XLRN at https://www.zacks.com/ap/XLRN